LMF Acquisition Opportunities, Inc. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2020 and is based in Tampa, Florida.
IPO Year: 2021
Exchange: NASDAQ
Website: lmfacquisitions.com
| Date | Price Target | Rating | Analyst |
|---|
8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
EFFECT - SeaStar Medical Holding Corp (0001831868) (Filer)
S-8 - SeaStar Medical Holding Corp (0001831868) (Filer)
S-3/A - SeaStar Medical Holding Corp (0001831868) (Filer)
8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
424B5 - SeaStar Medical Holding Corp (0001831868) (Filer)
8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
S-3 - SeaStar Medical Holding Corp (0001831868) (Filer)
8-K - SeaStar Medical Holding Corp (0001831868) (Filer)
Denver, Colo. and Tampa, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company, today announced the appointment of Dr. Sai Prasad N. Iyer, Ph.D to the position of Vice President, Medical Affairs and Clinical Development at SeaStar Medical, effective September 15, 2022. Dr. Iyer brings 20 years of industry experience and will provide leadership in developing and executing clinical trials, including SeaStar Medical's upcoming pivotal clinical trial of its Sel
DENVER, CO and TAMPA, FL, May 24, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Inc., a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company, today announced that Kevin Chung, MD will join SeaStar Medical as Chief Medical Officer (CMO), effective July 1, 2022. Dr. Chung brings over 20 years of experience as an accomplished critical care physician with expertise in extracorporeal life support therapies (ECLS). Since his fellowship training in critical care at Walter Reed Army Medical Center, Dr. Chung has treated thousands o
TAMPA, Fla., Aug. 16, 2021 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ:LMFA) ("LM Funding" or "LMFA"), a technology-based specialty finance company, today announced its financial results for the three and six months ended June 30, 2021. Financial Highlights for the Three and Six Month Period Ended June 30, 2021: Net income attributable to LM Funding for the three and six-month periods ended June 30, 2021 totaled $11.1 million or $2.05 per basic and diluted share and $15.5 million or $2.96 per basic and $2.95 per diluted share, respectively.Cash increased to $22.2 million or approximately $4.09 per basic and diluted share on June 30, 2021 as compared to $11.6 million
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
SC 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)
SC 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)
SC 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)
SC 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)
SC 13G/A - SeaStar Medical Holding Corp (0001831868) (Subject)
SC 13D - SeaStar Medical Holding Corp (0001831868) (Subject)
SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)
SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)
SC 13G - SeaStar Medical Holding Corp (0001831868) (Subject)
SC 13G/A - LMF Acquisition Opportunities Inc (0001831868) (Subject)
3 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4/A - SeaStar Medical Holding Corp (0001831868) (Issuer)
4/A - SeaStar Medical Holding Corp (0001831868) (Issuer)
4/A - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
4 - SeaStar Medical Holding Corp (0001831868) (Issuer)
– Company advancing clinically proven platform therapy, the Selective Cytopheretic Device (SCD), to address the life-threatening consequences of hyperinflammation – SCD lead program in Acute Kidney Injury (AKI) with potential FDA approval for pediatric AKI targeted for Q1 2023 and commencement of pivotal trial in adult AKI targeted in Q1 2023 – Ongoing exploratory clinical research to refine patient populations where SCD may be effective to fuel pipeline with potential in high-value hyperinflammatory indications– SeaStar Medical commenced trading on Nasdaq under the ticker "ICU" today, Monday, October 31st Denver, Colorado, Oct. 31, 2022 (GLOBE NEWSWIRE) -- SeaStar Med
LMF Acquisition Opportunities Renamed SeaStar Medical Holding Corporation SeaStar Medical Holding Corporation Common Stock and Warrants to Commence Trading on Nasdaq Under New Ticker Symbol "ICU" and "ICUCW" DENVER and TAMPA, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that it has completed its previously announced business combination with LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ:LMFA). The business combination closed on October
DENVER and TAMPA, Fla., Oct. 18, 2022 (GLOBE NEWSWIRE) -- LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ:LMFA), and SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that LMAO stockholders voted to approve the previously proposed business combination with SeaStar Medical at LMAO's special meeting of LMAO stockholders (the "Special Meeting") held earlier today, October 18, 2022. More than 96% of the votes cast at the meeting voted to approve the business combination with SeaStar Med
All stockholders of LMF Acquisition Opportunities as of September 23, 2022 are encouraged to vote their shares as soon as possible before the special meeting Stockholders who need assistance voting their shares should contact LMF Acquisition Opportunities' proxy solicitor, Alliance Advisors, toll-free at (855) 935-2548 or by email to [email protected] Following closing, the combined company's common stock and warrants are expected to trade under the ticker symbols "ICU" and "ICUCW", respectively DENVER and TAMPA, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America
Denver, Colo. and Tampa, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company, today announced the appointment of Dr. Sai Prasad N. Iyer, Ph.D to the position of Vice President, Medical Affairs and Clinical Development at SeaStar Medical, effective September 15, 2022. Dr. Iyer brings 20 years of industry experience and will provide leadership in developing and executing clinical trials, including SeaStar Medical's upcoming pivotal clinical trial of its Sel
DENVER, CO and TAMPA, FL, Aug. 01, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company, today announced that SeaStar Medical's novel Selective Cytopheretic Device (SCD) was successfully used in a pediatric patient with hemophagocytic lymphohistiocytosis (HLH), a dysregulated immune disorder in children associated with Epstein Barr virus (EBV), the virus that causes mononucleosis. In its most severe form, HLH presents with signs and symptoms of hyperinflammation that can progre
TAMPA, FL, July 29, 2022 (GLOBE NEWSWIRE) -- LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (the "Company") announced today that its board of directors has elected to extend the date by which the Company has to consummate a business combination from July 29, 2022 to October 29, 2022 (the "Extension"), as permitted under the Company's Amended and Restated Certificate of Incorporation. In connection with the Extension, the Company's sponsor, LMFAO Sponsor, LLC, has notified the Company that it intends to deposit an aggregate of $1,035,000 (representing $0.10 per public share) into the Company's trust account on or before July 29, 2022. The Extension provides the Company with additional ti
DENVER, CO and TAMPA, FL, July 20, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company, today announced SeaStar Medical has submitted its application to the U.S. Food and Drug Administration ("FDA") for Humanitarian Device Exemption (HDE) for use of the Selective Cytopheretic Device (SCD) for critically-ill children with acute kidney injury (AKI). The FDA informed SeaStar Medical that it has accepted the application and will begin its review. The SCD is an extracorporeal devi
DENVER, CO and TAMPA, FL, June 07, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company, today announced the publication of results from SeaStar Medical's pilot SCD 005 clinical study to evaluate the safety and clinical outcomes of extracorporeal immunomodulation treatment with SeaStar Medical's Selective Cytopheretic Device (SCD) in COVID-19 patients with multiple organ failure in the intensive care unit (ICU). The article, "Extracorporeal Immunomodulation Treatment and Clinical
DENVER, CO and TAMPA, FL, May 24, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Inc., a medical technology company developing a platform therapy to reduce the consequences of hyperinflammation on vital organs, and LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company, today announced that Kevin Chung, MD will join SeaStar Medical as Chief Medical Officer (CMO), effective July 1, 2022. Dr. Chung brings over 20 years of experience as an accomplished critical care physician with expertise in extracorporeal life support therapies (ECLS). Since his fellowship training in critical care at Walter Reed Army Medical Center, Dr. Chung has treated thousands o
LMF Acquisition Opportunities Renamed SeaStar Medical Holding Corporation SeaStar Medical Holding Corporation Common Stock and Warrants to Commence Trading on Nasdaq Under New Ticker Symbol "ICU" and "ICUCW" DENVER and TAMPA, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical, Inc., a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, today announced that it has completed its previously announced business combination with LMF Acquisition Opportunities, Inc. (NASDAQ:LMAO) (LMAO), a special purpose acquisition company sponsored by LM Funding America, Inc. (NASDAQ:LMFA). The business combination closed on October
Gainers UserTesting, Inc. (NYSE:USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also reported better-than-expected Q3 sales results. AgroFresh Solutions, Inc. (NASDAQ:AGFS) climbed 71.3% to close at $2.69 after the company announced its board of directors agreed with Paine Schwartz Partners to pursue acquisition of the company for $3 per share. HeartCore Enterprises, Inc. (NASDAQ:HTCR) shares jumped 57.3% to close at $1.51 on Thursday after the company announced it entered into a license agreement with Transcosmos Digital Technology for its Apromore process mining tool. Altra
Gainers ESSA Pharma Inc. (NASDAQ:EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate Cancer Foundation Scientific Retreat. OneConnect Financial Technology Co., Ltd. (NASDAQ:OCFT) surged 45.8% to close at $0.9040. RLX Technology Inc. (NYSE:RLX) jumped 43% to close at $1.63. Cipher Mining Inc. (NASDAQ:CIFR) gained 42.6% to close at $1.18. Loyalty Ventures Inc. (NASDAQ:LYLT) jumped 39.6% to close at $1.15. Eqonex Limited (NASDAQ:EQOS) climbed 38.2% to close at $0.47. Freight Technologies, Inc. (NASDAQ:FRGT) gained 37.4% to close at $0.5910. Freight Te
Gainers NextPlay Technologies, Inc. (NASDAQ:NXTP) shares climbed 107.3% to close at $0.4138 on Thursday after the company announced its NextFintech division received commitment for a $15 million strategic investment. Ascent Solar Technologies, Inc. (NASDAQ:ASTI) surged 57.5% to close at $5.12. Ascent Solar recently named Jeffrey Max as CEO. Quanergy Systems, Inc. (NYSE:QNGY) gained 51.2% to settle at $1.89. Cabaletta Bio, Inc. (NASDAQ:CABA) jumped 50.8% to close at $1.96. Cabaletta Bio President and CEO Steven Nichtberger acquired a total of 8,127 shares at an average price of $1.25. Save Foods, Inc. (NASDAQ:SVFD) gained 31.3% to close at $1.97. FingerMotion, Inc. (NASDAQ:FNGR) rose
Gainers NextPlay Technologies, Inc. (NASDAQ:NXTP) shares jumped 126% to $0.4525 after the company announced its NextFintech division received commitment for a $15 million strategic investment. Ascent Solar Technologies, Inc. (NASDAQ:ASTI) gained 44.1% to $4.6852. Ascent Solar recently named Jeffrey Max as CEO. American Rebel Holdings, Inc. (NASDAQ:AREB) rose 32.4% to $0.3640 after the company announced it sees $5 million in pro forma Q3 gross revenue. Alfi, Inc. (NASDAQ:ALF) jumped 30.8% to $0.3390. Rubicon Technologies, Inc. (NYSE:RBT) gained 30.3% to $2.5790. NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) rose 26% to $4.65. NGM Biopharmaceuticals Director David Goeddel V bought a total
Gainers Amprius Technologies, Inc. (NYSE:AMPX) jumped 77.3% to settle at $11.01 on Wednesday after the company announced it was awarded a $50 million cost-sharing grant from the U.S. Department of Energy's Office of Manufacturing and Energy Supply Chains. Mullen Automotive, Inc. (NASDAQ:MULN) gained 57.1% to close at $0.34 after the company announced US Bankruptcy Court approval of its acquisition of ELMS assets. The company will acquire ELMS's manufacturing plant, inventory and intellectual property. Scopus BioPharma Inc. (NASDAQ:SCPS) surged 51.6% to close at $0.3720. Scopus Biopharma completed recapitalization designed to enhance shareholder value. SenesTech, Inc. (NASDAQ:SNES) shar
Gainers SenesTech, Inc. (NASDAQ:SNES) shares jumped 102.6% to $0.47 after declining over 3% on Tuesday. SenesTech, during August, posted a Q2 loss of $0.21 per share. Scopus BioPharma Inc. (NASDAQ:SCPS) rose 66% to $0.4075. Scopus Biopharma completed recapitalization designed to enhance shareholder value. RedHill Biopharma Ltd. (NASDAQ:RDHL) gained 61.6% to $0.75 after the company announced its oral broad-acting antiviral, Opaganib, was granted a new COVID-19 treatment patent. Kintara Therapeutics, Inc. (NASDAQ:KTRA) jumped 40% to $0.1401. The company announced it paused its REM-001 program to conserve funds to support its VAL-083 international registrational study. HV Bancorp, Inc.